A novel nasal nanotherapy activates the STING immune pathway using spherical gold-cored nucleic acids, enabling non-invasive treatment of aggressive glioblastoma tumors in mice. This treatment elicits a strong immune response in specific immune cells in the tumor and surrounding lymph nodes while minimizing the spread of the drug throughout the body, reducing the risk of side effects. Combined with drugs that increase T-cell activity, the nanodrops completely eliminated tumors and produced long-term immunity in mice. Previous methods required direct injections into the tumor, which was invasive and impractical with repeated doses. The new approach uses the nasal route to transport the drug to the brain, making it less burdensome for the patient. Research shows that activation of the STING pathway changes the tumor's immune environment from suppressive to antitumor. However, the researchers caution that STING activation alone may not be sufficient for a complete cure and plan to add additional immune mechanisms to the nanotherapy to increase efficacy. This study represents a promising new direction for brain cancer immunotherapy[4][6][7].